Lindus Health and Quotient Sciences have announced a strategic partnership to enable enhanced patient recruitment and streamlined pathways for clinical trials.
The partnership will address the industry challenge posed by biotechnology and pharmaceutical companies needing to engage with multiple vendors across pre-clinical and clinical phases, causing inefficiencies and operational delays. Quotient’s expertise in early clinical and drug development will be integrated with Lindus’ expertise in patient recruitment and later-stage trial delivery.
Quotient conducts over 70 phase 1 studies annually across its US and UK clinics. Its Translational Pharmaceutics model allows for speedy progression from formulation to first-in-human (FIH) trials. However, early phase studies require highly specific patient populations: Lindus’ omnichannel approach provides access to over 40 million electronic medical records (EMRs), enabling comprehensive support for patient recruitment.
Together, the companies will eliminate the need for independent sourcing of separate vendors for each stage of the drug development process. This will streamline clinical development, reducing administrative burden on sponsors and ultimately accelerating the delivery of new drugs to patients.
“This partnership underscores our commitment to removing bottlenecks in the clinical development lifecycle,” said Michael Young, co-CEO of Lindus. “By collaborating with Quotient, we are creating a comprehensive development pathway that allows biotech companies to move through a contiguous experience from FIH studies through to pivotal trials.”
Matt Paterson, chief strategy officer at Quotient, added: “Early-phase programmes increasingly demand patient cohorts and rapid iteration. By pairing Lindus’ recruitment engine with our early clinical development expertise and Translational Pharmaceutics platform, sponsors can move seamlessly from FIH into later-stage trials with fewer handoffs, clearer decision-making and materially shorter timelines.”
